XML 46 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Earnings Per Share (Tables)
12 Months Ended
Jun. 30, 2018
Earnings Per Share [Abstract]  
Reconciliation of the numerators and denominators used in the basic and diluted earnings per common share computations
 
Year Ended June 30,
 
2018
 
2017
 
2016
Numerator
 
 
 
 
 
Net income (loss)
$
1,712

 
$
(1,792
)
 
$
(56,024
)
Income allocated to participating securities
(19
)
 

 

Net income (loss) available to common stockholders
$
1,693

 
$
(1,792
)
 
$
(56,024
)
Denominator
 
 
 
 
 
Weighted average common shares outstanding — basic
33,145,140

 
32,373,709

 
32,537,621

Effect of dilutive stock options(1)
15,039

 

 

Effect of dilutive restricted stock units(2)
335,869

 

 

Effect of performance-based restricted stock awards (3)
118,212

 

 

Weighted average common shares outstanding — diluted
33,614,260

 
32,373,709

 
32,537,621

 
 
 
 
 
 
Earnings per common share — basic
$
0.05

 
$
(0.06
)
 
$
(1.72
)
Earnings per common share — diluted
$
0.05

 
$
(0.06
)
 
$
(1.72
)
 
 
 
 
 
 

(1)
At June 30, 2018, 2017, and 2016; 22,321, 78,201, and 606,879 stock options, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these options has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
(2)
At June 30, 2018, 2017, and 2016; 335,869, 349,430 and 304,816 additional shares of common stock, respectively, were issuable upon the settlement of outstanding restricted stock units. The effect of the shares that would be issued upon settlement of these restricted stock units has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.
(3)
At June 30, 2018 and 2017, 531,178 and 318,584, respectively, of performance-based restricted stock awards were outstanding. The effect of the shares that would be issued upon vesting of these awards has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.